Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

Published

Journal Article

This article summarizes the final conclusions of the National Lipid Association (NLA) Statin Safety Task Force, based on a review and independent research of New Drug Application (NDA) information, US Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) data, cohort and clinical trial results, and analysis of administrative claims database information and the assessment of its 4 Expert Panels, which focused on issues of statin safety with regard to liver, muscle, renal, and neurologic systems. Practical guidance in the form of recommendations to health professionals who manage the coronary artery disease risk of patients with statin therapy is provided.

Full Text

Duke Authors

Cited Authors

  • McKenney, JM; Davidson, MH; Jacobson, TA; Guyton, JR; National Lipid Association Statin Safety Assessment Task Force,

Published Date

  • April 2006

Published In

Volume / Issue

  • 97 / 8A

Start / End Page

  • 89C - 94C

PubMed ID

  • 16581336

Pubmed Central ID

  • 16581336

Electronic International Standard Serial Number (EISSN)

  • 1879-1913

International Standard Serial Number (ISSN)

  • 0002-9149

Digital Object Identifier (DOI)

  • 10.1016/j.amjcard.2006.02.030

Language

  • eng